Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 7, 2023, Editas Medicine, Inc. (the "Company") and Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer of the Company, agreed that Dr. Shearman will step down as Chief Scientific Officer effective March 31, 2023. Pursuant to the terms of an agreement (the "Separation Agreement") dated as of January 7, 2023, Dr. Shearman will receive (i) his base salary for a period of 12 months following the date of his separation (the "Severance Period"), (ii) company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act for the Severance Period, and (iii) the amount of any unpaid annual bonus determined by the Company's Board of Directors to be payable to him for the 2022 calendar year. All payments and benefits provided under the Separation Agreement are contingent upon the execution and effectiveness of, and Dr. Shearman's continued compliance with, a release of claims agreement between Dr. Shearman and the Company. The Separation Agreement also contains standard non-disparagement and confidentiality provisions.

© Edgar Online, source Glimpses